Last reviewed · How we verify
placebo of Bacillus Calmette - Guerin
placebo of Bacillus Calmette - Guerin is a Biologic drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. It is currently in Phase 3 development for Severe forms of tuberculosis, such as TB meningitis and miliary TB. Also known as: placebo of BCG.
The Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated vaccine that stimulates a cell-mediated immune response against Mycobacterium tuberculosis.
The Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated vaccine that stimulates a cell-mediated immune response against Mycobacterium tuberculosis. Used for Severe forms of tuberculosis, such as TB meningitis and miliary TB.
At a glance
| Generic name | placebo of Bacillus Calmette - Guerin |
|---|---|
| Also known as | placebo of BCG |
| Sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
BCG vaccine works by introducing a weakened form of the bacteria that causes tuberculosis, which triggers an immune response that helps the body fight off the infection. This immune response is thought to provide long-term protection against severe forms of tuberculosis, such as TB meningitis and miliary TB. The exact mechanisms of how BCG vaccine provides protection against tuberculosis are not fully understood.
Approved indications
- Severe forms of tuberculosis, such as TB meningitis and miliary TB
Common side effects
- Local reaction at injection site
Key clinical trials
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (PHASE1, PHASE2)
- First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (PHASE1)
- Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau (PHASE4)
- Immunization With BCG Vaccine to Prevent Tuberculosis Infection (PHASE3)
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (PHASE1)
- A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (PHASE2)
- Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes (PHASE2)
- Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo of Bacillus Calmette - Guerin CI brief — competitive landscape report
- placebo of Bacillus Calmette - Guerin updates RSS · CI watch RSS
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. portfolio CI
Frequently asked questions about placebo of Bacillus Calmette - Guerin
What is placebo of Bacillus Calmette - Guerin?
How does placebo of Bacillus Calmette - Guerin work?
What is placebo of Bacillus Calmette - Guerin used for?
Who makes placebo of Bacillus Calmette - Guerin?
Is placebo of Bacillus Calmette - Guerin also known as anything else?
What development phase is placebo of Bacillus Calmette - Guerin in?
What are the side effects of placebo of Bacillus Calmette - Guerin?
Related
- Manufacturer: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Severe forms of tuberculosis, such as TB meningitis and miliary TB
- Also known as: placebo of BCG
- Compare: placebo of Bacillus Calmette - Guerin vs similar drugs
- Pricing: placebo of Bacillus Calmette - Guerin cost, discount & access